Lake Street Private Wealth LLC Has $222,000 Stock Position in Danaher Co. (NYSE:DHR)

Lake Street Private Wealth LLC reduced its holdings in Danaher Co. (NYSE:DHR) by 28.6% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 797 shares of the conglomerate’s stock after selling 319 shares during the quarter. Lake Street Private Wealth LLC’s holdings in Danaher were worth $222,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the business. Tsfg LLC lifted its position in shares of Danaher by 733.3% during the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after acquiring an additional 88 shares during the period. nVerses Capital LLC acquired a new position in shares of Danaher during the second quarter valued at about $25,000. CarsonAllaria Wealth Management Ltd. bought a new position in shares of Danaher during the 2nd quarter worth about $25,000. Redmont Wealth Advisors LLC acquired a new stake in shares of Danaher in the 1st quarter valued at about $30,000. Finally, MFA Wealth Advisors LLC bought a new stake in Danaher in the 2nd quarter valued at about $51,000. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Trading Down 2.0 %

NYSE DHR opened at $256.00 on Thursday. The business’s fifty day moving average is $270.43 and its 200-day moving average is $260.43. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04. The stock has a market capitalization of $189.62 billion, a price-to-earnings ratio of 43.39, a PEG ratio of 4.49 and a beta of 0.83. Danaher Co. has a one year low of $182.09 and a one year high of $281.70.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, topping the consensus estimate of $1.57 by $0.14. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The business had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.59 billion. During the same quarter in the previous year, the firm posted $2.02 earnings per share. The company’s revenue for the quarter was up 3.1% on a year-over-year basis. Equities research analysts predict that Danaher Co. will post 7.59 EPS for the current year.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Friday, September 27th will be given a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.42%. The ex-dividend date is Friday, September 27th. Danaher’s dividend payout ratio is currently 18.31%.

Wall Street Analyst Weigh In

DHR has been the subject of a number of research reports. KeyCorp raised their price objective on Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a research note on Wednesday. TD Cowen boosted their price target on shares of Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a research note on Wednesday. Wells Fargo & Company started coverage on shares of Danaher in a research note on Tuesday, August 27th. They issued an “equal weight” rating and a $280.00 price objective on the stock. Leerink Partners boosted their target price on shares of Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 24th. Finally, Raymond James dropped their price target on shares of Danaher from $310.00 to $300.00 and set an “outperform” rating on the stock in a research report on Wednesday. Seven analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat.com, Danaher has a consensus rating of “Moderate Buy” and a consensus price target of $287.28.

Insider Buying and Selling at Danaher

In other news, CEO Rainer Blair sold 9,007 shares of the company’s stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the transaction, the chief executive officer now owns 97,983 shares of the company’s stock, valued at $27,435,240. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CEO Rainer Blair sold 9,007 shares of the firm’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the transaction, the chief executive officer now directly owns 97,983 shares of the company’s stock, valued at approximately $27,435,240. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Georgeann Couchara sold 952 shares of the business’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the sale, the senior vice president now owns 4,212 shares in the company, valued at approximately $1,130,374.44. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 30,059 shares of company stock worth $8,400,897 over the last ninety days. 11.10% of the stock is currently owned by company insiders.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.